Hello, and welcome to the 2021 Annual Meeting of Stockholders of Elrond Therapeutics Inc. Please note that today's meeting is being recorded. You can submit questions at any time by clicking on the message icon. It is now my pleasure to turn today's meeting over to Manuel Alvaro, President and Chief Executive Officer of Elrond Therapeutics, Inc. Doctor.
Alvaro, the floor is yours.
Good morning, and welcome to the 2021 Annual Meeting of Stockholders of Aileron Therapeutics. I am Manuel Alvaro, President and Chief Executive Officer of Aileron, and I will be presiding over this meeting. At this time, I call the meeting to order. As last year, we are holding our annual meeting in a virtual format and are pleased to have everyone join this live webcast. We have designed this meeting to provide stockholders the same rights and opportunities to participate as they would at an in person meeting.
Before we get to the formal part of the meeting, I would like to make some introductions. Joining us at the meeting today are Jeff Bailey, the Chairman of our Board our Corporate Directors, Reinhard Ambros, William McKee, Jody Morrison, Nolan Sigel and Joe Koniggenbach, as well as our management team, namely Richard Mondstall, Chief Financial Officer and Treasurer Allen Annis, Senior Vice President, Research Roy Vukovich, Senior Vice President and Chief Medical Officer Andrze Brainski, Vice President, Clinical Development and Dora Ferrari, Vice President, Clinical Operations and Program Management. I would also like to introduce Stuart Haber of WilmerHale, the company's legal counsel Karen Fell, a representative of PricewaterhouseCoopers, our independent registered public accounting firm and finally, Chris Ciaricci, a representative from Computershare Trust Company, our transfer agent who has been appointed to act as Inspector of Election. In order to conduct an orderly meeting, I call your attention to the rules of conduct posted on the virtual meeting website, which include information about participating in the meeting, including asking questions. Please note that various remarks that we may make about future expectations, plans and prospects for the company constitute forward looking statements for purpose of Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent quarterly report on Form 10 Q, which is on file with the SEC. In addition, these forward looking statements represent the company's expectations only as of today. While the company may elect to update these forward looking statements, it specifically disclaims any obligation to do so. Any forward looking statements should not be relied upon as representing the company's estimates or views as of any date subsequent to today. I received an affidavit from the company's transfer agent from Peter Share Trust Company certifying that the notice of the annual meeting and proxy statement were sent to all stockholders of record as of April 23, 2021.
Our first order of business at this meeting is to determine whether the shares represented at this meeting, either in person via this virtual meeting or by proxy, are sufficient to constitute a quorum or purpose of transacting business. Holders of 90,297,848 shares of common stock are entitled to vote at this meeting. The Inspector of Election has informed me that there are present at this meeting either in person or by proxy a total of 57,798,304 shares of common stock or approximately 64% of all shares entitled to vote at this meeting. Therefore, I hereby declare that Cor resists. Turning now to the items to be voted on at this meeting.
As indicated in the notice of meeting and accompanying documents that were made available to stockholders, the first matter to be voted on is the election of 2 Class 1 directors to serve until the 2024 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The nominees for election are Jeff Bailey and Jody Morrissey. The second matter to be voted on is the approval of an amendment to our certificate of incorporation to increase the number of authorized shares of common stock from $150,000,000 to $300,000,000 The 3rd letter to be voted on is the approval of our 2021 stock incentive plan. The 4th and final letter to be voted on is the ratification of the appointment of PricewaterhouseCoopers as our independent registered public accounting firm for the fiscal year ending December 31, 2021. If there are any questions on the proposals, they may be submitted on the virtual meeting website.
By asking a question, please also include your name and affiliation to the company. Rick, do we have any questions at this time? There are no questions at this time. Seeing no questions, we'll move on to voting on the proposals. I hereby declare the polls are now open for each matter to be voted upon today.
If you have not yet voted or if you previously voted by proxy and wish to change your vote, you may vote by using the cast your vote link provided on the virtual meeting website and following the instructions there. We will now briefly pause to allow stockholders to vote. Now that everyone has had an opportunity to vote, the business items on the agenda for this meeting are complete and the calls are now closed. Patti, would you please tabulate the votes? Thank you, Betty.
We now have the preliminary report of the results of the meeting. Based on this report, each of the nominees for directors has been elected as a Class I director. The amendment to our certificate of incorporation to increase the number of authorized shares of common stock from $150,000,000 to $300,000,000 has been approved. The 2021 stock incentive plan has also been approved and the appointment of PWC has been ratified. The final vote results will be included in the Form 8 ks that will be filed within 4 business days after this meeting.
As there is no further business to come before the meeting, I declare the formal part of this meeting adjourned. We'll now use our remaining available time to answer appropriate questions from stockholders. Please I see there are no questions. And therefore, I say thank you again for attending the meeting and goodbye. Operator?